Drug Profile
SER 287
Alternative Names: Purified encapsulated eubacterial spore suspension; SER-287Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Seres Therapeutics
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ulcerative colitis
Most Recent Events
- 07 Dec 2022 SER 287 is still in phase II for ulcerative colitis (Seres Therapeutics, pipeline December 2022)
- 17 Dec 2021 Efficacy data from phase IIb trial in Ulcerative colitis released by Seres Therapeutics
- 13 Oct 2021 Seres Therapeutics terminates phase IIb ECO-RESET trial in Ulcerative colitis (Treatment-experienced, In adults, In the elderly) in US and Canada (NCT03759041)